The EMEA Pharmacovigilance Working Party, which regulates pharmaceuticals oversight in the European Union, now contraindicts Magnevist and Omniscan for the following cases:
- Patients with severe renal impairment (glomular filtration rate or estimated GFR <30 mL/min)
- Neonates and infants up to one year of age
- Patients who have had a liver transplant or are awaiting liver transplantation.
It also suggests that both agents should be used with caution in patients with moderate renal impairment (GRF or eGFR from 30 to 59 mL/min) and that all patients should be screened for renal dysfunction prior to gadolinium-enhanced MRI, through questions about history of disease and/or lab tests.
Latest Articles
The EMEA Pharmacovigilance Working Party, which regulates pharmaceuticals oversight in the European Union, now contraindicts Magnevist and Omniscan for t...
